Open AccessStudy of Riamilovir Activity Against SARS-CoV-2 Infection In Syrian Hamsters
Author(s) -
С. В. Чепур,
Anna V. Smirnova,
A. N. Kirienko,
I. A. Myasnikova,
B. A. Kanevsky,
P. Sorokin
Publication year - 2021
Publication title -
antibiotiki i himioterapiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.112
H-Index - 11
ISSN - 0235-2990
DOI - 10.37489/0235-2990-2021-66-7-8-13-19
Subject(s) - hamster , syrian hamsters , nasal administration , virology , spleen , vero cell , drug , virus , mesocricetus , medicine , pharmacology , antiviral drug , covid-19 , immunology , pathology , infectious disease (medical specialty) , disease
The activity of the antimetabolic drug Riamilovir (Triazavirin ® ) was studied on a model of SARS-CoV-2 infection on Syrian hamsters. Infectious process was caused by the intranasal administration of the virus accumulated in the Vero-B culture with a concentration of 4.25×10 4 TCID 50 , in a volume of 26 µl/hamster. The eects of the drug at a dose of 20 mg/kg intraperitoneally daily in the midst of the infectious process were traced to accelerate the clearance of the virus in the lungs, prevent body weight loss and the severity of pulmonary edema, as well as preserve the mass of the spleen. The protective eects of Riamilovir on the structure of the lungs and brain are shown, it is suggested that the drug has the ability to penetrate the blood-brain barrier. It was concluded that Riamilovir has antiviral activity against SARS-CoV-2.